Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27577203 | 1.00 | EPHX1 (0.53) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL8956480 | 0.84 | HDAC1 (0.45) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL19910579 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL14076747 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL11035085 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL24072564 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL25454649 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL5059517 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL10248180 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 | |
| SCHEMBL16410230 | 0.80 | EPHX1 (0.61) | EPHX1MMP8DPP7RRM1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | EPHX1 3137/4885MMP8 298/4885DPP7 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.